Dendritic Cell (DC) Vaccine for Malignant Glioma and Glioblastoma

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

August 21, 2013

Primary Completion Date

November 7, 2018

Study Completion Date

July 16, 2022

Conditions
Malignant GliomaGlioblastoma MultiformeAnaplastic AstrocytomaHigh Grade Glioma
Interventions
BIOLOGICAL

Dendritic Cell Vaccine

Between 1.2 to 12 million DC per dose administered once a week via intradermal injection for 4 weeks.

BIOLOGICAL

Tumor Lysate

Post-DC Vaccine therapy. Up to 1.5 mg of Lysate of tumor per dose administered via intradermal injection at intervals defined by study protocol.

DRUG

Imiquimod

5% topical cream applied to vaccine site before and after administrations of DC vaccine or lysate

PROCEDURE

Leukapheresis

Baseline, post-surgery blood draw via catheter to obtain peripheral blood mononuclear cells (PBMCs) from which Dendritic cells will be obtained.

Trial Locations (1)

33136

University of Miami, Miami

All Listed Sponsors
lead

Macarena De La Fuente, MD

OTHER

NCT01808820 - Dendritic Cell (DC) Vaccine for Malignant Glioma and Glioblastoma | Biotech Hunter | Biotech Hunter